{"id":195,"date":"2026-02-27T13:01:10","date_gmt":"2026-02-27T18:01:10","guid":{"rendered":"https:\/\/www.eye-connect.org\/rvo\/?page_id=195"},"modified":"2026-03-03T11:48:03","modified_gmt":"2026-03-03T16:48:03","slug":"1403-3","status":"publish","type":"page","link":"https:\/\/www.eye-connect.org\/rvo\/1403-3\/","title":{"rendered":"Accredited Activity A1403-3"},"content":{"rendered":"<section class=\"l-section wpb_row height_auto\"><div class=\"l-section-h i-cf\"><div class=\"g-cols vc_row via_grid cols_1 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_middle type_default stacking_default\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-separator size_medium\"><\/div><div class=\"g-cols wpb_row via_grid cols_1 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_middle type_default stacking_default\" style=\"--columns-gap:3rem;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><h1 style=\"text-align: center;\">Accredited Activity<\/h1>\n<\/div><\/div><div class=\"w-separator size_medium\"><\/div><\/div><\/div><\/div><div class=\"g-cols wpb_row via_grid cols_2-1 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_top type_default stacking_default\" style=\"--columns-gap:3rem;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_left\"><div class=\"w-image-h\"><img decoding=\"async\" width=\"850\" height=\"478\" src=\"https:\/\/www.eye-connect.org\/rvo\/wp-content\/uploads\/2026\/03\/A1403-3-PoV-RVO-Management-Ver2.png\" class=\"attachment-full size-full\" alt=\"RVO Management - PoV\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/rvo\/wp-content\/uploads\/2026\/03\/A1403-3-PoV-RVO-Management-Ver2.png 850w, https:\/\/www.eye-connect.org\/rvo\/wp-content\/uploads\/2026\/03\/A1403-3-PoV-RVO-Management-Ver2-300x169.png 300w, https:\/\/www.eye-connect.org\/rvo\/wp-content\/uploads\/2026\/03\/A1403-3-PoV-RVO-Management-Ver2-130x73.png 130w\" sizes=\"auto, (max-width: 850px) 100vw, 850px\" \/><\/div><\/div><div class=\"w-separator size_small\"><\/div><div class=\"w-tabs change-tabs-list-bg3 layout_hor style_modern switch_hover has_scrolling\" style=\"--sections-title-size:1em\"><div class=\"w-tabs-list items_4 align_none\" style=\"font-weight:400;\"><div class=\"w-tabs-list-h\"><button class=\"w-tabs-item active\" aria-controls=\"content-v1f9\" aria-expanded=\"false\"><span class=\"w-tabs-item-title\">Overview<\/span><\/button><button class=\"w-tabs-item\" aria-controls=\"content-t48a\" aria-expanded=\"false\"><span class=\"w-tabs-item-title\">Learning Objectives<\/span><\/button><button class=\"w-tabs-item\" aria-controls=\"content-na51\" aria-expanded=\"false\"><span class=\"w-tabs-item-title\">Faculty &amp; Disclosures<\/span><\/button><button class=\"w-tabs-item\" aria-controls=\"content-m3b6\" aria-expanded=\"false\"><span class=\"w-tabs-item-title\">CME Information<\/span><\/button><\/div><\/div><div class=\"w-tabs-sections titles-align_none icon_chevron cpos_right\"><div class=\"w-tabs-section active\" id=\"v1f9\"><button class=\"w-tabs-section-header active\" aria-controls=\"content-v1f9\" aria-expanded=\"true\"><h6 class=\"w-tabs-section-title\">Overview<\/h6><div class=\"w-tabs-section-control\"><\/div><\/button><div  class=\"w-tabs-section-content\" id=\"content-v1f9\"><div class=\"w-tabs-section-content-h i-cf\"><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><h5><u>Overview<\/u><\/h5>\n<p>Many patients with macular edema secondary to retinal vein occlusion (RVO) require lifelong intensive therapy. Join Dr Ip as he presents a case illustrating the challenge of managing patients who require monthly or near monthly dosing. See if you share his management approach for these difficult-to-treat patients. Dr Ip also discusses recent publications that highlight the relationship between anatomic biomarkers and disease status. Importantly, he considers anatomic biomarkers that might provide additional clues as to why visual acuity worsens following cessation of very frequent dosing (eg monthly or near monthly) while optical coherence tomography central subfield thickness is overall stable.<\/p>\n<h5><u>Target Audience<\/u><\/h5>\n<p>This activity is designed to meet the educational needs of retina specialists and other treating ophthalmologists.<\/p>\n<h5><u>Educational Provider<\/u><\/h5>\n<div>This activity is provided by the American Academy of Ophthalmology, with support from Paradigm Medical Communications, LLC.<\/div>\n<h5><u>Supporter Acknowledgment <\/u><\/h5>\n<p>This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.<\/p>\n<\/div><\/div><\/div><\/div><\/div><div class=\"w-tabs-section\" id=\"t48a\"><button class=\"w-tabs-section-header\" aria-controls=\"content-t48a\" aria-expanded=\"false\"><h6 class=\"w-tabs-section-title\">Learning Objectives<\/h6><div class=\"w-tabs-section-control\"><\/div><\/button><div  class=\"w-tabs-section-content\" id=\"content-t48a\"><div class=\"w-tabs-section-content-h i-cf\"><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><h5><u>Learning Objectives<\/u><\/h5>\n<p>Upon completion of this activity, participants should be able to:<\/p>\n<ul>\n<li>Summarize factors that may suggest a need for more intensive, long-term treatment of RVO<\/li>\n<\/ul>\n<\/div><\/div><\/div><\/div><\/div><div class=\"w-tabs-section\" id=\"na51\"><button class=\"w-tabs-section-header\" aria-controls=\"content-na51\" aria-expanded=\"false\"><h6 class=\"w-tabs-section-title\">Faculty &amp; Disclosures<\/h6><div class=\"w-tabs-section-control\"><\/div><\/button><div  class=\"w-tabs-section-content\" id=\"content-na51\"><div class=\"w-tabs-section-content-h i-cf\"><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><h5><u>Faculty &amp; Disclosures <\/u><\/h5>\n<p><strong>Faculty<\/strong><br \/>\n<strong>Michael S. Ip, MD<\/strong><br \/>\nProfessor<br \/>\nDepartment of Ophthalmology<br \/>\nDavid Geffen School of Medicine at UCLA<br \/>\nDoheny Eye Institute UCLA<br \/>\nPasadena, CA<\/p>\n<p><strong>Scientific Integrity and Disclosure of Financial Interest<\/strong><\/p>\n<p>The American Academy of Ophthalmology is committed to ensuring that all continuing medical education (CME) information is based on the application of research findings and the implementation of evidence-based medicine. It seeks to promote balance, objectivity and absence of commercial bias in its content. All persons in a position to control the content of this activity must disclose any and all financial interests. The Academy has mechanisms in place to resolve all conflicts of interest prior to an educational activity being delivered to the learners.<\/p>\n<p>In accordance with the ACCME <em>Standards for Integrity and Independence in Accredited Continuing Education<\/em>, the Academy requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months.<\/p>\n<p>All relevant relationships are identified and mitigated according to the Academy\u2019s policy prior to individuals assuming their roles, and are disclosed prior to learners\u2019 engagement in the activity. The Academy is committed to providing learners with high-quality accredited continuing education that promotes improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.<\/p>\n<p>The content of this activity was independently reviewed to ensure that it is fair and balanced, scientifically rigorous, evidence based, and aligned with the public interest.<\/p>\n<p>A full listing of financial disclosures can be found below. All relevant financial relationships have been mitigated.<\/p>\n<p><strong>Faculty:<\/strong><br \/>\n<strong>Michael S. Ip, MD<\/strong><br \/>\n<em>Consultant\/Advisor:<\/em> 4DMT; Adverum; Alimera Sciences, Inc.; Allergan, Inc.; Amgen Inc; Apellis Pharmaceuticals, Inc.; Aviceda; Biogen MA, Inc.; Cell Lineage Therapeutics; Clearside Biomedical, Inc.; GENENTECH; Iveric Bio; Novartis Pharma AG; Occurx; ONL Therapeutics; Regeneron Pharmaceuticals, Inc.; REGENXBIO<\/p>\n<p><strong>Content Reviewer:<\/strong><br \/>\n<strong>Jay C. Wang, MD<\/strong><br \/>\n<em>Consultant\/Advisor:<\/em> Carl Zeiss Meditec<\/p>\n<p><strong>Rahul N. Khurana, MD<\/strong><br \/>\n<em>Consultant\/Advisor:<\/em> Abbvie; Annexion; Bausch + Lomb; GENENTECH; REGENXBIO<br \/>\n<em>Grant Support:<\/em> Alcon Laboratories, Inc.; Annexion; Boehringer Ingelheim; GENENTECH; Opthea; REGENXBIO<br \/>\n<em>Independent Contractor:<\/em> Regeneron Pharmaceuticals, Inc.<\/p>\n<p>The American Academy of Ophthalmology and Paradigm staff members have no relevant financial relationships with ineligible companies to disclose.<\/p>\n<\/div><\/div><\/div><\/div><\/div><div class=\"w-tabs-section\" id=\"m3b6\"><button class=\"w-tabs-section-header\" aria-controls=\"content-m3b6\" aria-expanded=\"false\"><h6 class=\"w-tabs-section-title\">CME Information<\/h6><div class=\"w-tabs-section-control\"><\/div><\/button><div  class=\"w-tabs-section-content\" id=\"content-m3b6\"><div class=\"w-tabs-section-content-h i-cf\"><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><h5><u>CME Information<\/u><\/h5>\n<p><strong>CME for Physicians<br \/>\n<\/strong>The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.<\/p>\n<p><strong>Designation Statement<br \/>\n<\/strong>The American Academy of Ophthalmology designates this enduring material for a maximum of 0.25 <em>AMA PRA Category 1 Credit<\/em>\u2122. Physicians should claim only the credit commensurate with the extent of their participation in the activity.<\/p>\n<p><strong>Instructions for Participation<br \/>\n<\/strong>To receive a certificate and claim credit, participants must:<\/p>\n<ul>\n<li>Follow instructions to register or log in with your professional information and complete the pretest<\/li>\n<li>View the online activity in its entirety<\/li>\n<li>Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest<\/li>\n<\/ul>\n<p>A certificate of participation will be available for download\/printing immediately following your successful completion of the posttest and evaluation.<\/p>\n<p>For questions regarding CME credit, contact the American Academy of Ophthalmology at <a href=\"mailto:cme@aao.org\">cme@aao.org<\/a>.<\/p>\n<p>There are no fees for participating in this activity.<\/p>\n<p><strong>Hardware\/Software Requirements<br \/>\n<\/strong>This accredited CME activity is designed using HTML5 web components.<\/p>\n<p><strong>Supported\u00a0Browsers (Desktop\/Mobile)<br \/>\n<\/strong>Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+<br \/>\n<strong><br \/>\nPDF documents<\/strong><br \/>\nThis activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: <a href=\"http:\/\/get.adobe.com\/reader\">http:\/\/get.adobe.com\/reader<\/a><\/p>\n<p><strong>Technical Support<br \/>\n<\/strong>If you have any technical problems or playback issues, email us at <a href=\"mailto:contactus@paradigmmc.com\">contactus@paradigmmc.com<\/a>.<\/p>\n<p><strong>Disclosure of Unlabeled Use<br \/>\n<\/strong>This educational activity may contain discussion of published and\/or investigational uses of agents that are not approved by the FDA.<\/p>\n<p><strong>Disclaimer<br \/>\n<\/strong>This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, the American Academy of Ophthalmology and Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.<br \/>\nIf included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.<br \/>\nAs an ACCME-accredited provider, the American Academy of Ophthalmology must ensure that its activities include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by the American Academy of Ophthalmology.<\/p>\n<p><strong>Terms of Use and Privacy Policy<br \/>\n<\/strong><u>Disclaimer<br \/>\n<\/u>The materials provided for this activity are for informational purposes only and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by the American Academy of Ophthalmology and Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by the American Academy of Ophthalmology and Paradigm Medical Communications, LLC. The American Academy of Ophthalmology and Paradigm Medical Communications, LLC accept no liability for the content referenced in this activity.<\/p>\n<p><u>Privacy policy<br \/>\n<\/u>Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as \u201cwebsite\u201d). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.<\/p>\n<p><u>Security\/safeguarding personal information<br \/>\n<\/u>This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.<\/p>\n<p><u>Collection and use of your personal information<br \/>\n<\/u>The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program <span>and may be used to track registration and participation<\/span>. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.<\/p>\n<p>Paradigm Medical Communications, LLC does not otherwise transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants\u2019 credits.<\/p>\n<p><strong>Contact Us<\/strong><br \/>\nIf you have any questions or comments, please email us at <a href=\"mailto:contactus@paradigmmc.com\">contactus@paradigmmc.com<\/a>.<\/p>\n<p>\u00a9 2026 American Academy of Ophthalmology except where noted. Content may not be reproduced in whole or part without the express written permission of the American Academy of Ophthalmology.<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><div class=\"wpb_column vc_column_container us_custom_255f7bea\"><div class=\"vc_column-inner\"><div class=\"wpb_text_column us_custom_f062bb91\"><div class=\"wpb_wrapper\"><div style=\"font-size: 18px;\"><strong>Points of View<\/strong><br \/>\n<strong>Release Date:<\/strong> March 6, 2026<br \/>\n<strong>Expiration Date:<\/strong> March 6, 2027<br \/>\n<strong>Time to Complete:<\/strong> 15 minutes<br \/>\n<strong>Credit: <\/strong>0.25 hour<\/div>\n<div>\n<p>&nbsp;<\/p>\n<\/div>\n<div style=\"font-size: 18px;\"><strong>Credit Type<\/strong>: <em>AMA PRA Category 1 Credit<\/em>\u2122<em><br \/>\n<\/em><strong>Target Audience<\/strong>: Retina specialists and other treating ophthalmologists<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_1\" target=\"_blank\" href=\"https:\/\/ce.paradigmmc.com\/a\/DYRDYD\"><span class=\"w-btn-label\">START ACTIVITY<\/span><\/a><\/div><div class=\"w-separator size_large\"><\/div><\/div><\/div><\/div><div class=\"w-separator size_small\"><\/div><\/div><\/div><\/div><\/div><\/section><section class=\"l-section wpb_row height_small\"><div class=\"l-section-h i-cf\"><div class=\"g-cols vc_row via_grid cols_1 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_top type_default stacking_default\"><div class=\"wpb_column vc_column_container us_custom_c1126334\"><div class=\"vc_column-inner\"><div class=\"w-html\"><hr style=\"height:1px;border-width:0;color:#5d4c84;background-color:#5d4c84;\"><\/div><\/div><\/div><\/div><\/div><\/section>\n","protected":false},"excerpt":{"rendered":"Accredited Activity OverviewLearning ObjectivesFaculty &amp; DisclosuresCME InformationOverviewOverview Many patients with macular edema secondary to retinal vein occlusion (RVO) require lifelong intensive therapy. Join Dr Ip as he presents a case illustrating the challenge of managing patients who require monthly or near monthly dosing. See if you share his management approach for these difficult-to-treat patients. Dr...","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-195","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.eye-connect.org\/rvo\/wp-json\/wp\/v2\/pages\/195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.eye-connect.org\/rvo\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.eye-connect.org\/rvo\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.eye-connect.org\/rvo\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.eye-connect.org\/rvo\/wp-json\/wp\/v2\/comments?post=195"}],"version-history":[{"count":5,"href":"https:\/\/www.eye-connect.org\/rvo\/wp-json\/wp\/v2\/pages\/195\/revisions"}],"predecessor-version":[{"id":209,"href":"https:\/\/www.eye-connect.org\/rvo\/wp-json\/wp\/v2\/pages\/195\/revisions\/209"}],"wp:attachment":[{"href":"https:\/\/www.eye-connect.org\/rvo\/wp-json\/wp\/v2\/media?parent=195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}